ReviewImmunotherapy2013
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
Review in Immunotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis.Clinical rheumatology · 2017Pooled it
- Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Clinical rheumatology · 2016Pooled it
- Amelioration of human osteoarthritis symptoms with topical 'biotherapeutics': a phase I human trial.Cell stress & chaperones · 2015Trial
- Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Do LRG1-SERPINA1 Interactions Modulate Fibrotic and Inflammatory Signatures in Rheumatoid Arthritis? A Proteomic and In Silico Investigation.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.International ophthalmology · 2025Article
- Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- Investigation of TNF-α and IL-6 Levels in the Sera of Non-Melanoma Skin Cancer Patients.Iranian biomedical journal · 2021Article
- Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response.International journal of molecular sciences · 2020Review
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin.Oncotarget · 2018Article
- Risk of gastrointestinal events among patients with sarcoidosis: a population-based study 1976-2013.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.Radiation research · 2017Article
- Sinusitis in patients on tumor necrosis factor alpha inhibitors.International forum of allergy & rhinology · 2017Article
- TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis.Scientific reports · 2016Article
- A Drug Delivery System for Administration of Anti-TNF-α Antibody.Translational vision science & technology · 2016Article
- Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.British dental journal · 2015Review
- Cat scratch disease during infliximab therapy: a case report and literature review.Rheumatology international · 2015Review
- IL-6 biology: implications for clinical targeting in rheumatic disease.Nature reviews. Rheumatology · 2014Review
- Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection.Journal of Korean medical science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.